215 related articles for article (PubMed ID: 33140956)
1. Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein-Protein Interactions.
Shi Y; Sang P; Lu J; Higbee P; Chen L; Yang L; Odom T; Daughdrill G; Chen J; Cai J
J Med Chem; 2020 Nov; 63(21):13187-13196. PubMed ID: 33140956
[TBL] [Abstract][Full Text] [Related]
2. Sulfono-γ-AApeptides as Helical Mimetics: Crystal Structures and Applications.
Sang P; Shi Y; Huang B; Xue S; Odom T; Cai J
Acc Chem Res; 2020 Oct; 53(10):2425-2442. PubMed ID: 32940995
[TBL] [Abstract][Full Text] [Related]
3. α-Helix-Mimicking Sulfono-γ-AApeptide Inhibitors for p53-MDM2/MDMX Protein-Protein Interactions.
Sang P; Shi Y; Lu J; Chen L; Yang L; Borcherds W; Abdulkadir S; Li Q; Daughdrill G; Chen J; Cai J
J Med Chem; 2020 Feb; 63(3):975-986. PubMed ID: 31971801
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
[TBL] [Abstract][Full Text] [Related]
5. Discovery of α-helix-mimicking sulfono-γ-AApeptides as p53-MDM2 inhibitors.
Shi Y; Sang P; Cai J
Future Med Chem; 2021 Jun; 13(12):1021-1023. PubMed ID: 33906432
[No Abstract] [Full Text] [Related]
6. Rational Design and Synthesis of Right-Handed d-Sulfono-γ-AApeptide Helical Foldamers as Potent Inhibitors of Protein-Protein Interactions.
Sang P; Shi Y; Higbee P; Wang M; Abdulkadir S; Lu J; Daughdrill G; Chen J; Cai J
J Org Chem; 2020 Aug; 85(16):10552-10560. PubMed ID: 32700908
[TBL] [Abstract][Full Text] [Related]
7. d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
Li X; Liu C; Chen S; Hu H; Su J; Zou Y
Bioorg Med Chem Lett; 2017 Oct; 27(20):4678-4681. PubMed ID: 28916339
[TBL] [Abstract][Full Text] [Related]
8. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
9. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
Zondlo SC; Lee AE; Zondlo NJ
Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
11. Sulfono-γ-AApeptides as a new class of nonnatural helical foldamer.
Wu H; Qiao Q; Hu Y; Teng P; Gao W; Zuo X; Wojtas L; Larsen RW; Ma S; Cai J
Chemistry; 2015 Feb; 21(6):2501-7. PubMed ID: 25504756
[TBL] [Abstract][Full Text] [Related]
12. Effect of sequence and stereochemistry reversal on p53 peptide mimicry.
Atzori A; Baker AE; Chiu M; Bryce RA; Bonnet P
PLoS One; 2013; 8(7):e68723. PubMed ID: 23922660
[TBL] [Abstract][Full Text] [Related]
13. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
14. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
15. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
16. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
17. Isolation of a peptide containing d-amino acid residues that inhibits the α-helix-mediated p53-MDM2 interaction from a one-bead one-compound library.
Morimoto J; Hosono Y; Sando S
Bioorg Med Chem Lett; 2018 Feb; 28(3):231-234. PubMed ID: 29326019
[TBL] [Abstract][Full Text] [Related]
18. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
19. Multicomponent Peptide Stapling as a Diversity-Driven Tool for the Development of Inhibitors of Protein-Protein Interactions.
Ricardo MG; Ali AM; Plewka J; Surmiak E; Labuzek B; Neochoritis CG; Atmaj J; Skalniak L; Zhang R; Holak TA; Groves M; Rivera DG; Dömling A
Angew Chem Int Ed Engl; 2020 Mar; 59(13):5235-5241. PubMed ID: 31944488
[TBL] [Abstract][Full Text] [Related]
20. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
